Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA2B | P08514 | 17/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359637 | 0.89 | ITGA2B (0.56) | ITGA2BITGB3CKS1BSKP1SKP2 | |
| SCHEMBL367846 | 0.89 | ITGA2B (0.66) | ITGA2BLMNAITGB3CKS1BSKP1 | |
| SCHEMBL368258 | 0.88 | ITGA2B (0.67) | ITGA2BITGB3CKS1BSKP1SKP2 | |
| SCHEMBL15130116 | 0.87 | ITGA2B (0.45) | ITGA2BITGB3CKS1BSKP1SKP2 | |
| SCHEMBL369864 | 0.86 | ALPL (0.56) | ITGA2BLMNAITGB3CKS1BSKP1 | |
| SCHEMBL368502 | 0.86 | ABCB1 (0.46) | LMNACKS1BSKP1SKP2MAPT | |
| SCHEMBL371348 | 0.84 | ITGA2B (0.62) | ITGA2BITGB3CKS1BSKP1SKP2 | |
| SCHEMBL15137944 | 0.84 | ALDH1A1 (0.44) | ITGA2BLMNACKS1BSKP1SKP2 | |
| SCHEMBL30270968 | 0.84 | ACKR3 (0.49) | ITGA2BLMNAITGB3CKS1BSKP1 | |
| SCHEMBL369303 | 0.83 | ITGA2B (0.51) | ITGA2BLMNAITGB3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532989-B2 | Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150374697-A1 | ORGANIC COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-12-31 | — | — | US | disclosed |
| US-9066948-B2 | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130251761-A1 | ORGANIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| EP-2593106-A1 | ORGANIC COMPOUNDS | Rockefeller University (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009688-A1 | ORGANIC COMPOUNDS | ROCKEFELLER UNIVERSITY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374697-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | ITGA2B 255/4885LMNA 3156/4885ITGB3 75/4885 |
| US-20130251761-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | ITGA2B 255/4885LMNA 3156/4885ITGB3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.